Sixty-nine patients with a history of low-grade B-cell nonHodgkin's lymphoma (NHL) in sensitive relapse or incomplete first remission underwent high-dose chemoradiotherapy and anti-B-cell monoclonal antibody (MoAb)-treated autologous bone marrow transplantation (ABMT). At ABMT, 51 patients had low-grade histology and 18 patients had a history of low-grade NHL that had undergone histologic transformation to a higher-grade NHL. Before ABMT, only 20 of the 51 low-grade patients and 10 of the 18 patients with transformed histologies were in complete remission. Moreover, at the time of marrow harvest, 24 of the low-grade and eight of the transformed histology patients had histologic EW, IF ANY, patients with advanced-stage low-grade F non-Hodgkin's lymphoma (NHL) are curable with conventional therapy."' Although many of these patients often achieve a complete remission (CR) with standard treatment, the median duration of first CR is often short (ranging from 12 to 36 months).'-6 More importantly, in most studies advanced-stage patients ultimately relapse, with a disease-free survival (DFS) of only 25% at 5 years.' The implementation of more aggressive chemotherapeutic regimens has led to higher CR rates yet the overall survival in most studies appears to be unchanged. Although lowgrade lymphomas are still responsive following relapse, the duration of subsequent responses progressively d e c r e a s e~?~~~ Moreover, between 15% to 70% of low-grade NHL eventually undergo histologic conversion to a higher-grade histology that has been associated with a poor prognosis.'.'' High-dose therapy and autologous bone marrow transplantation (ABMT) has been shown to be a potentially curative modality for patients with relapsed intermediate/ high-grade NHL.'2-W Considering the large numbers of patients who have undergone ABMT for NHL, relatively few with relapsed low-grade histologies have been treated with this a p p r~a c h . '~~'~~'~~~~ The lack of interest for ABMT in low-grade lymphomas has largely been based on the belief that this is a disease with a very long natural history where 
evidence of lymphoma cells infiltrating the marrow. Following high-dose therapy, only one acute, in-hospital death was observed. There was no significant difference in the diseasefree survival (DFS) between patients with low-grade and patients with transformed histologies. Among patients with low-grade NHL, the patients in complete remission before ABMT experienced significantly longer DFS than those in partial remission (P < .05). This preliminary study suggests that some patients with relapsed low-grade NHL may experience prolonged DFS following high-dose ablative therapy.
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excessive treatment-related toxicities associated with aggressive therapy would not be acceptable. Moreover, the high frequency of overt BM infiltration, even following aggressive chemotherapeutic regimens, has been a major obstacle. To date, fewer than 100 patients with low-grade NHL have undergone ABMT ~o r l d w i d e . '~~'~*~~-'~ Many of these patients had disease resistant to conventional therapy before ABMT and the vast majority were selected for lack of BM infiltration.
In the present study, we report the results of 69 patients with a history of low-grade B-cell NHL who were treated with high-dose chemoradiotherapy and anti-B-cell monoclonal antibody (MoAb)-purged ABMT. Although followup is limited, this treatment approach may provide prolonged DFS for some patients with low-grade NHL.
MATERIALS AND METHODS

Selection of patients and treatment protocol.
Patients were eligible for this study if they were less than 65 years of age; had relapsed low-grade NHL as defined by the International Working Formulation (WF), after standard chemotherapeutic regimens; and had lymphoma cells that expressed the CD20 (Bl) antigen as previously described.'' In addition, patients with sensitive low-grade NHL but who had failed to enter CR after one or more standard chemotherapeutic regimens were eligible. For all patients, a minimal disease status had to be attained through chemotherapy, radiotherapy, or both before entry. This status was defined as lymph nodal mass less than 2 cm in its greatest diameter and histologic evidence of BM involvement of 20% or less of the intratrabecular space as determined by iliac crest biopsy. Additional criteria for entry included the absence of comorbid disease of the heart, kidney, lung, and liver and a Karnofsky score above 80%. Active central nervous system involvement with lymphoma or any circumstance that would obviate the ability to deliver full-dose total body irradiation (TBI) excluded patients from the protocol. Informed consent was obtained from all patients.
Preparative therapy consisted of cyclophosphamide, 60 mgikg of body weight, infused on each of 2 consecutive days before radiotherapy. TBI was administered in fractionated doses (200 cGy) twice daily on 3 consecutive days (total of 1,200 cGy) in all patients. Supportive care was provided as previously de~cribed.'~ Eighteen patients were enrolled on a randomized study of granulocytemacrophage colony-stimulating factor (GM-CSF) versus placebo, 10 of whom received GM-CSF.
BM was obCollection, processing, and infusion of marrow. Evaluation and statistical analysk. Before treatment, all patients were evaluated by physical examination, blood-chemistry profile, complete blood count, chest X ray, abdominal-pelvic computed tomography (CT) scanning (chest CT if indicated), BM aspirate and biopsy, as well as cell surface phenotypic studies of peripheral blood and BM mononuclear cells. Other studies such as gallium scanning were performed as needed to determine the extent of disease. Follow-up restaging was performed every 6 months after transplantation or as clinically indicated.
CR was defined as the disappearance of all measurable and evaluable disease. Failure were defined as relapse of disease or toxic death. DFS was calculated from the day of marrow transplantation (day 0). DFS curves were estimated by the method of Kaplan and Meier, confidence intervals using Greenwood's formula, and compared by the log rank
The multiple comparisons analysis was performed using the Bonferroni correction.26
RESULTS
Patient characteristics.
Sixty-nine patients with B-cell NHL in sensitive relapse or incomplete first remission who attained a minimal disease state underwent ABMT (between 12/82 and 11/89, Table l). Fifty-one of these patients (median age 42) retained a low-grade histology at ABMT (49 follicular and 2 diffuse), whereas 18 patients (median age 43) had a history of low-grade NHL that had undergone histologic transformation to an intermediate-grade NHL. At diagnosis, 48 of the 69 patients had follicular small cleaved cell (FSC) histology. Patients whose lymphoma underwent histologic transformation generally had diffuse histology at ABMT, the majority were either diffuse largecell lymphoma (DLC) (n = 7) or diffuse mixed small-and large-cell lymphoma (DM) (n = 5). The majority of patients with both low-grade or transformed histology had a history of BM infiltration at some time during the course of their disease.
All patients were previously treated with combination chemotherapy (Table 2 ). The median number of regimens with which patients were treated was three for both low-grade and transformed histology patients (range two to eight for transformed, two to seven for low grade). Approximately one-third received prior involved field radiotherapy and two patients had been previously treated with Prior therapy. 
TBI (150 cGy)
. A CR at anytime during their disease course (including at the time of BM harvest) was documented in only 35 (69%) of the low-grade patients (median prior longest disease-free interval 8 months, range 2 to 66 months). Fourteen (78%) of the transformed patients had previously achieved a CR (median prior longest diseasefree interval 7 months, range 3 to 87 months). At BM harvest, only 20 of the 51 low-grade patients were in CR. Of the 31 patients who only attained a minimal disease state, 24 had residual BM involvement. In contrast, 10 of the 18 patients with transformed histologies were in CR before For
One patient with FSC NHL died an acute, in-hospital treatment-related death due to thrombocytopenic cerebral hemorrhage that occurred on day 20. Two late deaths from non-lymphomatous causes were observed. One of the patients with transformed histology who had received low-dose TBI 10 years before ABMT, multiple chemotherapeutic regimens, and involved field radiation therapy to the pelvis developed acute nonlymphocytic leukemia at 47 months, and died without evidence of lymphoma following an HLA-matched allogenic BMT (at 49 months). An additional patient with follicular mixed small and large cell lymphoma (FM) treated with multiple chemotherapeutic regimens and involved field radiotherapy died of a myelodysplastic syndrome at 14 months, 2 months after BM relapse with lymphoma.
A life table analysis (Table 3 ) depicts the number of failures, the length of follow-up, and the Kaplan-Meier estimates of the proportion of patients surviving without disease at yearly intervals. Failures have been defined as relapse of disease or treatment-related death, and censored patients are those who are known to be disease-free and alive during the indicated interval. As of 8/1/90, 9 of 51 patients who retained low-grade histology and 10 of 18 patients with transformed histologies have been followed for more than 2 years. Therefore, the long-term follow-up of these patients is limited. There was no significant difference in the 2-year DFS between the patients with low-grade and transformed NHL ( P = .2) (Fig 1) . The Kaplan-Meier estimate of the percentage of patients alive and disease-free at 2 years is 53% for the low-grade patients (95% confidence interval ranging from 36% to 71%) and 88% for the transformed patients (95% confidence interval ranging from 71% to 100%). However, estimate of the percentage of transformed patients alive and disease-free Treatment outcome. .23
*Patients censored at 4.9 and 5.0 years. tPatient censored at 7.6 years. at 4 years is 23% (95% confidence interval ranging from 0% to 60%).
Of the 23 patients who relapsed, the overwhelming majority of patients with both low-grade (n = 18) and transformed histologies (n = 5 ) relapsed in sites of prior disease ( Table 4) . Entirely Factors that might exert an adverse effect on DFS among the 51 patients who retain low-grade histologies include: (1) no history of CR, ( 2 ) extranodal disease, (3) lymphomatous marrow infiltration at any time during the disease course, (4) a partial remission (PR) rather than CR at ABMT, and (5) overt marrow involvement with lymphoma at BM harvest. Using the Bonferroni correction for multiple comparisons, only PR versus CR at ABMT was significantly (P < .05) associated with adverse DFS (Fig 2) . The interval from diagnosis to ABMT was also examined, and it was found that patients transplanted within 3.5 years of diagnosis have fewer relapses than expected (P = .04). However, using the Bonferroni correction, this finding was not statistically significant. 
DISCUSSION
Following first relapse, the long-term prognosis for patients with low-grade NHL is poor, with a median survival of approximately 5 years.* Although relapsed patients can achieve subsequent remissions with single-agent as well as combination chemotherapy, the median DFS is 12 to 24 months at best. It is now generally accepted that high-dose ablative therapy and ABMT is a potentially curative modality for patients with relapsed intermediatehigh-grade NHL. However, the use of this approach for patients with lowgrade histology has been limited. Over the past 7 years at our institution, 69 patients with a history of low-grade B-cell NHL have undergone high-dose therapy and anti-B-cell MoAb-purged ABMT. This group of patients represents the largest number of low-grade NHL patients treated with this modality at a single center to date. A detailed examination of these patients suggests that a subgroup of these heavily pretreated, relapsed patients can attain and remain in CR, suggesting a potential role for this modality in the treatment of low-grade NHL.
This study differs from most reports of ABMT in relapsed NHL because patients with low-grade histology have been included. Two report^**^*^ have recently examined the treatment results of ABMT in patients with a history of follicular lymphoma. In these studies, virtually all patients were selected for uninvolved BM at harvest. In the present study, 61% of patients had some residual disease at harvest, and 47% had BM infiltration with lymphoma, which is consistent with the high frequency of BM involvement in low-grade NHL. In contrast to patients with intermediate/ high-grade NHL who have undergone ABMT, patients with low-grade histology who had residual disease at ABMT had a significantly worse DFS than patients in clinical CR. Although controversial, several series have demonstrated that selected patients with intermediateihigh-grade NHL who undergo high-dose therapy with residual but sensitive disease have a similar DFS to patients in CR at ABMT.'*,*7328 The present study suggests that patients with low-grade NHL who could attain a CR before ABMT have an improved DFS over patients with residual disease at ABMT. Our patients were treated with multiple aggressive salvage regimens in an attempt to attain a minimal disease state or CR before ABMT. Therefore, many of those who were transplanted with residual disease, either in BM or nodal sites, most likely harbored residual resistant lymphoma.
The treatment outcome for patients who have undergone histologic transformation using conventional therapy has been reported to be p00r.~',*~ The limited number of studies which have included patients with transformed NHL who have undergone ABMT report a high treatment-related mortality and low DFS.20*2z Our patients with transformed histologies had disease that was still sensitive to conventional therapy. This finding is in contrast to other reports of ABMT in histologic transformation and is likely to account for the observed differences in treatment-associated mortality and DFS.
The majority of studies using high-dose therapy and ABMT in NHL have included patients with no evidence of marrow involvement with lymphoma at harvest. Because it is clear that patients with histologically uninvolved BM and peripheral blood can have residual lymphoma cells, as detected by sensitive techniques molecular techniques, the reinfusion of tumor-involved autologous marrow or peripheral blood is at least a theoretical c o n~e r n ?~"~ Four reports have attempted to deal with this problem in patients with low-grade NHL. Three studies have reported the use of anti-B-cell MoAbs and complement in the treatment of patients with both histologically involved and uninvolved BM.15316,23 Another approach has been to use autologous peripheral blood stem cells as an alternative to autologous marrow.33 In the present study we are unable to determine whether relapse results from endogenous residual tumor cells or from reinfused tumor cells contaminating the BM. Because the majority of relapses occur in sites of prior bulk disease that may not have been completely eradicated by the conditioning regimen, tumor cells reinfused with the BM may not contribute to relapse. Alternatively, the observation that six of the eight BM relapses occurred in patients with marrow involvement at harvest might suggest that reinfused tumor cells preferentially "home" to the marrow.
Although longer follow-up will be necessary to determine if high-dose therapy and ABMT improves the DFS over conventional chemotherapy alone, the present study and others suggest that some patients with relapsed low-grade NHL experience prolonged DFS following high-dose therapy and ABMT. Because the long-term DFS following ABMT for relapsed patients with intermediate/high-grade NHL is predicted to be approximately 40%, perhaps high-dose therapy may improve the DFS for patients with incurable low-grade NHL. A report from Young et al using aggressive combination chemotherapy and total nodal radiotherapy suggests delayed intensive treatment will lead to a lower probability of achieving CR and, therefore, the chance of long-term cure.34
Another approach to previously untreated patients with low-grade NHL would be to use high-dose therapy and ABMT in first remission. Considering the very low treatment-associated mortality for relapsed patients with sensitive NHL undergoing ABMT, earlier treatment may be For personal use only. on November 15, 2017. by guest www.bloodjournal.org From justified for patients with incurable lymphoma. Low-grade NHL may be analogous to chronic myelogenous leukemia (CML), which was deemed incurable until BMT was e~aluated.~~.~' It is generally accepted that allogeneic BMT for CML in accelerated phase or blast crisis is inferior to that seen in chronic p h a~e .~~"~ Moreover, earlier BMT for patients in chronic-phase CML appears to lead to an even better DFS. 37 The investigation of the role of more intensive treatment strategies for low-grade NHL may demonstrate a similar finding.
